9783319429236-331942923X-Ketamine for Treatment-Resistant Depression: The First Decade of Progress

Ketamine for Treatment-Resistant Depression: The First Decade of Progress

ISBN-13: 9783319429236
ISBN-10: 331942923X
Edition: 1st ed. 2016
Publication date: 2016
Publisher: Springer
Format: Hardcover 174 pages
FREE shipping on ALL orders

Book details

ISBN-13: 9783319429236
ISBN-10: 331942923X
Edition: 1st ed. 2016
Publication date: 2016
Publisher: Springer
Format: Hardcover 174 pages

Summary

Acknowledged author wrote Ketamine for Treatment-Resistant Depression: The First Decade of Progress comprising 174 pages back in 2016. Textbook and eTextbook are published under ISBN 331942923X and 9783319429236. Since then Ketamine for Treatment-Resistant Depression: The First Decade of Progress textbook was available to sell back to BooksRun online for the top buyback price or rent at the marketplace.

Description

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants.

Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose.

This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Rate this book Rate this book

We would LOVE it if you could help us and other readers by reviewing the book